Upgrade for Complete Access See Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKesson
Dow
Johnson and Johnson
Mallinckrodt
McKinsey
AstraZeneca

Last Updated: November 28, 2021

DrugPatentWatch Database Preview

Patent: 7,638,335

➤ Subscribe for complete access

« Back to Dashboard

Summary for Patent: 7,638,335
Title:Kit comprising antihuman TNF-.alpha. antibody and antihuman TNF-.alpha. antibody activity lowering inhibitor
Abstract: The present invention provides an antihuman TNF-.alpha. antibody activity lowering inhibitor comprising a protein source(s) and/or carbohydrate source(s), in the treatment of inflammatory bowel syndrome with repeated administration of anti-TNF-.alpha. antibody; and a kit preparation wherein a freeze-dried antihuman TNF-.alpha. antibody and the activity lowering inhibitor in the above repeated administration of the anti-TNF-.alpha. antibody are separately contained in a plastic container so that they can communicate with each other. According to the present invention, in the drug therapy to the patients with inflammatory bowel syndrome, therapeutic agents which inhibit the inflammation for long periods without accompanying serious side effects can be provided.
Inventor(s): Matsumoto; Takayuki (Fukuoka, JP)
Assignee: AJINOMOTO Co., Inc. (Tokyo, JP)
Application Number:11/514,225
Patent Claims:see list of patent claims

Details for Patent 7,638,335

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Janssen Biotech, Inc. REMICADE infliximab For Injection 103772 1998-08-24 ⤷  Free Forever Trial 2024-03-01
Immunex Corporation ENBREL etanercept For Injection 103795 1998-11-02 ⤷  Free Forever Trial 2024-03-01
Immunex Corporation ENBREL etanercept For Injection 103795 1999-05-27 ⤷  Free Forever Trial 2024-03-01
Immunex Corporation ENBREL etanercept Injection 103795 2004-09-27 ⤷  Free Forever Trial 2024-03-01
Immunex Corporation ENBREL etanercept Injection 103795 2007-02-01 ⤷  Free Forever Trial 2024-03-01
Immunex Corporation ENBREL MINI etanercept Injection 103795 2017-09-14 ⤷  Free Forever Trial 2024-03-01
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Boehringer Ingelheim
Johnson and Johnson
AstraZeneca
Colorcon
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.